Ipca Laboratories Ltd. Share Price & Stock Analysis

Ipca Laboratories Ltd. (NSE: IPCALAB, BSE: 524494) is a Mumbai, Maharashtra-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹49,178 Cr, it ranks #211 by market cap among the 6,197 Indian listed companies on FinBizNet, and #12 of 86 in Medicinal Chemicals and Botanical Products. At ₹1,889.90 (as of 16 Nov 2026), the share price is 7.3% below its 52-week high of ₹2,038.00 and 38.8% above its 52-week low of ₹1,361.70. The share price is up 44.4% over one year and up 4.9% over three months.

Key Metrics

Current Price₹1,889.90
Market Cap₹49,178 Cr
NSE SymbolIPCALAB
BSE Code524494
SectorHealth Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals
Sub-IndustryBiotechnology and Life Sciences > Medicinal Chemicals and Botanical Products
P/E Ratio42.4
Return on Equity13.22%
Return on Assets8.42%
52-Week Range₹1,361.70 – ₹2,038.00
1-Year Price Change+44.4%
3-Month Price Change+4.9%
Beta (1Y)-0.02
Dividend Yield0.31%
HeadquartersMumbai, Maharashtra
Websitewww.ipca.com

Latest Quarterly Results — Q2 FY27

Revenue₹2,910 Cr
Net Profit₹389 Cr
Net Margin13.4%
EPS (Basic)₹14.79
Basisconsolidated

Figures in ₹ crore, parsed from the company's exchange filing (XBRL).

Ipca Laboratories Ltd. Quarterly Revenue and Profit Trend

Ipca Laboratories Ltd. reported revenue of ₹2,910 Cr in Q2 FY27, up 13.8% from ₹2,557 Cr in Q2 FY26 and up 4.4% from ₹2,788 Cr in Q1 FY27. It posted a net profit of ₹389 Cr for the quarter, against a net profit of ₹281 Cr in Q2 FY26 (up 38.8%). Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹2,247 Cr (Q4 FY25) to ₹2,910 Cr (Q2 FY27). The company was profitable in each of these 7 quarters.

QuarterRevenueNet ProfitNet Margin
Q2 FY27₹2,910 Cr₹389 Cr13.4%
Q1 FY27₹2,788 Cr₹424 Cr15.2%
Q4 FY26₹2,388 Cr₹307 Cr12.8%
Q3 FY26₹2,393 Cr₹364 Cr15.2%
Q2 FY26₹2,557 Cr₹281 Cr11.0%
Q1 FY26₹2,309 Cr₹233 Cr10.1%
Q4 FY25₹2,247 Cr₹64 Cr2.8%

Consolidated figures (₹ crore, XBRL filings).

Shareholding and Delivery

Promoters held 44.72% of Ipca Laboratories Ltd.'s shares as of Sept 2026, unchanged from Sept 2025. Delivery averaged 55.4% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).

About Ipca Laboratories Ltd.

Ipca Laboratories Limited, an integrated pharmaceutical company, manufactures and markets formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India, Europe, Africa, the Americas, Asia, the Commonwealth of Independent States, and Australasia. The company offers APIs in anti-hypertensive, anti-malarial, diuretic, DMARD, anti-hypertensive, and anthelmintic therapeutic areas. It also provides generic and branded formulations in various therapeutic segments, including allergy, anti-neoplastic/cancer drugs, anti-arthritic, anti-epileptic, anti-hypertensive, cardiology, diabetes, dermatology, diabetology, emollients/protectives, fever, gastroenterology, helminthics, hepatoprotectives, immunosuppressant, infectious diseases, malaria, neurology, neuropathic pain, and NSAIDs, as well as nutraceuticals, ophthalmology, oral anti diabetes drug, orthopedics, probiotics, psychiatry, respiratory, rheumatology, and urology. The company also exports its products

Products and Services

1. Pharmaceuticals-This segment manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients for various therapeutic segments.

Business Segments

1. Pharmaceuticals-100%

Ipca Laboratories Ltd. vs Peers — Medicinal Chemicals and Botanical Products

CompanyMarket CapP/EROELatest Qtr Revenue1Y Change
Sun Pharmaceutical Industries Limited₹4,56,425 Cr39.514.72%₹16,199 Cr+11.2%
Laurus Labs Ltd₹1,31,242 Cr145.617.74%₹2,206 Cr+146.8%
Zydus Lifesciences Ltd₹1,19,651 Cr24.118.32%₹7,910 Cr+26.0%
Dr.Reddys Lab₹1,15,464 Cr26.911.52%₹8,698 Cr+14.5%
Cipla Limited₹1,14,712 Cr29.311.74%₹7,404 Cr-7.6%
Mankind Pharma₹1,09,870 Cr5712.45%₹4,338 Cr+16.7%
Aurobindo Pharma Ltd.₹1,05,150 Cr309.93%₹10,263 Cr+59.8%
Lupin Ltd₹92,087 Cr17.326.91%₹7,827 Cr+0.4%
Ipca Laboratories Ltd.₹49,178 Cr42.413.22%₹2,910 Cr+44.4%

Listed by market capitalisation. Ratios are shown for context only.

Frequently Asked Questions

What is the current share price of Ipca Laboratories Ltd.?

Ipca Laboratories Ltd. is trading at ₹1,889.90, with a market capitalisation of ₹49,178 Cr.

Which sector does Ipca Laboratories Ltd. belong to?

Ipca Laboratories Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).

What are the key financial ratios of Ipca Laboratories Ltd.?

Ipca Laboratories Ltd. has a P/E of 42.4 and a return on equity of 13.22%.

What is the stock symbol of Ipca Laboratories Ltd.?

Ipca Laboratories Ltd. is listed on the NSE under the symbol IPCALAB and on the BSE under the scrip code 524494.

How has Ipca Laboratories Ltd.'s share price moved over the past year?

Ipca Laboratories Ltd.'s share price is up 44.4% over one year and up 4.9% over three months. Its 52-week range is ₹1,361.70 to ₹2,038.00.

What were Ipca Laboratories Ltd.'s latest quarterly results?

In Q2 FY27, Ipca Laboratories Ltd. reported revenue of ₹2,910 Cr and net profit of ₹389 Cr, with basic EPS of ₹14.79 (consolidated, parsed from the company's exchange filing).

How have Ipca Laboratories Ltd.'s revenue and profit changed over the past year?

Ipca Laboratories Ltd. reported revenue of ₹2,910 Cr in Q2 FY27, up 13.8% from ₹2,557 Cr in Q2 FY26 and up 4.4% from ₹2,788 Cr in Q1 FY27.

What is the promoter holding in Ipca Laboratories Ltd.?

Promoters held 44.72% of Ipca Laboratories Ltd.'s shares as of Sept 2026, unchanged from Sept 2025.

More on FinBizNet

Data as of 16 Nov 2026. Descriptive market data only — not investment advice.